ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Eli Lilly Settles Cymbalta Withdrawal Lawsuits

Top Fibromyalgia Drug Tanks: Four Other Drugs On Way

When Retreat Means Advance: A Recovered Chronic Fatigue Syndrome/Fibromyalgia Patient Looks Back

A Genetic Panel for Fibromyalgia? The New Proove Genetic Test

Fibromyalgia Life Lessons - What You Need to Know.

Creating Intimacy Through Mindful Touch When You Live with Chronic Illness

The Psychosocial Disease – Has Fibromyalgia Been Captured by a Behavioral Paradigm?

Genes May Be Causing Neuroinflammation and Pain in Fibromyalgia

3 Fibromyalgia Struggles I’m Glad I Had

VIDEO: How does your brain respond to pain?

Print Page
Email Article

Half of CFS patients with high HHV-6 & EBV titers improve 30% or better on Valcyte: Montoya

  [ 10 votes ]   [ 1 Comment ] • October 16, 2012

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers
- Source: Journal of Medical Virology, Oct 10, 2012

By Tessa Watt, Jose G Montoya, et al.

[Note: Dr. Montoya has studied the impact of the antiviral valganciclovir (Valcyte®) on ME/CFS patients affected by these viruses for years. This report suggests longer term treatment may be linked to better response.]

Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein–Barr virus (EBV) IgG antibody titers [concentrations].

This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients.

An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks).

Antibody titers were considered high if:

• HHV-6 IgG was 1:320 or greater,

• EBV viral capsid antigen (VCA) IgG was 1:640 or greater,

• And EBV early antigen (EA) IgG was 1:160 or greater.

Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness.

Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning.

Thirty-two patients (52%) were categorized as responders.

Among these:

• 19 patients (59%) responded physically

• And 26 patients (81%) responded cognitively.

Baseline antibody titers showed no significant association with response.

After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002).

No significant difference was found between responders and non-responders among other variables analyzed.

Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies.

Longer valganciclovir treatment correlated with an improved response.

Source: Journal of Medical Virology, Oct 10, 2012;84(12), pp 1967-1974. DOI: 10.1002/jmv.23411, by Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, Bhangoo MS, Montoya JG. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Palo Alto, California; University of Michigan Medical School, Ann Arbor; David Geffen School of Medicine, UCLA, Los Angeles, California; Brigham and Women’s Hospital, Boston, Massachusetts; San Diego School of Medicine, University of California, USA. [Email: Jose G Montoya]

Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg FibroSleep™ Guaifenesin FA™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments Post a Comment

Longer valganciclovir treatment correlated with an improved response.
Posted by: IanH
Oct 16, 2012
It would have been great if this improved response over longer term treatment could have been enumerated.
Reply Reply
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Guaifenesin FA™ Guaifenesin FA™
Helps the Body Eliminate Excess Calcium and Phosphates
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
The Fast-Acting Solution for Healthy Digestive Function The Fast-Acting Solution for Healthy Digestive Function
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map